Bavarian Nordic’s mpox vaccine, Jynneos (MVA-BN), is set to be trialled in pregnant and breastfeeding women and infants. The Phase III trial (PregInPoxVac) will enrol around 350 pregnant women and 250 ...
clinicaltrialsarena on MSN12d
Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trialThe registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years ...
(Reuters) - An initial 899,000 vaccine doses have been allocated for 9 countries across Africa that have been hit hard by the ...
(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...
A clinical trial by the US National Institutes of Health (NIH) has shown that Bavarian Nordic’s mpox vaccine induced an antibody response in adolescents equivalent to that of adults. The interim ...
The World Health Organisation has okayed Bavarian Nordic's mpox vaccine for young persons, aged between 12 and 17, as they are particularly believed to be vulnerable to outbreaks of the viral ...
Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...
The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...
The World Health Organisation said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback